IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0848819
(2015-09-09)
|
등록번호 |
US-9603859
(2017-03-28)
|
발명자
/ 주소 |
- Genberg, Carl
- Savage, Paul B.
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
3 인용 특허 :
38 |
초록
▼
Disclosed are methods for increasing the rate of healing of a tissue wound by administering a composition including a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting wound healing in a subject in need of such promo
Disclosed are methods for increasing the rate of healing of a tissue wound by administering a composition including a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting wound healing in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of a tissue wound. Kits comprising such compositions and instructions on such methods are also contemplated herein.
대표청구항
▼
1. A method for increasing the rate of healing of a tissue wound, comprising: identifying a subject in need of accelerated healing of a tissue wound; andcontacting the tissue wound with an effective amount of a tissue treatment composition to increase the rate of healing thereof, the tissue treatmen
1. A method for increasing the rate of healing of a tissue wound, comprising: identifying a subject in need of accelerated healing of a tissue wound; andcontacting the tissue wound with an effective amount of a tissue treatment composition to increase the rate of healing thereof, the tissue treatment composition comprising a cationic steroidal anti-microbial (CSA) compound of Formula V, or a pharmaceutically acceptable salt thereof, that promotes would healing and comprises a steroidal group and a plurality of cationic groups attached thereto: where, rings A, B, C, and D are independently saturated, or are fully or partially unsaturated, provided that at least two of rings A, B, C, and D are saturated;m, n, p, and q are independently 0 or 1;R1, R2, R4, R5, R6, R8, R9, R10, R11, R13, R14, R15, R16, and R17 are independently selected from the group consisting of hydrogen and substituted or unsubstituted (C1-C6) alkyl; andR3, R7, and R12 are independently selected from the group consisting of hydrogen, hydroxyl, substituted or unsubstituted (C1-C18) alkyl, substituted or unsubstituted (C1-C18) hydroxyalkyl, substituted or unsubstituted (C1-C18) alkyloxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylcarboxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylamino-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylamino-(C1-C18) alkylamino, substituted or unsubstituted (C1-C18) alkylamino-(C1-C18) alkylamino-(C1-C18) alkylamino, substituted or unsubstituted (C1-C18) aminoalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylamino-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) haloalkyl, substituted or unsubstituted (C2-C6) alkenyl, substituted or unsubstituted (C2-C6) alkynyl, oxo, linking group attached to a second CSA, substituted or unsubstituted (C1-C18) aminoalkyloxy, substituted or unsubstituted (C1-C18) aminoalkyloxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) aminoalkylcarboxy, substituted or unsubstituted (C1-C18) aminoalkylaminocarbonyl, substituted or unsubstituted (C1-C18) aminoalkylcarboxamido, substituted or unsubstituted di(C1-C18 alkyl) aminoalkyl, substituted or unsubstituted C-carboxy-(C1-C18) alkyl, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, substituted or unsubstituted (C1-C18) azidoalkyloxy, substituted or unsubstituted (C1-C18) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O, substituted or unsubstituted (C1-C18) guanidinoalkyloxy, substituted or unsubstituted (C1-C18) quaternary ammonium alkyl carboxy, and substituted or unsubstituted (C1-C18) guanidinoalkylcarboxy, where Q5 is a side chain of an amino acid and P.G. is an amino protecting group, provided that at least two of R3, R7, and R12 are not hydrogen; andR18 is selected from the group consisting of hydroxyl, substituted or unsubstituted (C1-C18) alkyl, substituted or unsubstituted (C1-C18) hydroxyalkyl, substituted or unsubstituted (C1-C18) alkyloxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylcarboxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylamino-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylamino-(C1-C18) alkylamino, substituted or unsubstituted amido, substituted or unsubstituted (C1-C18) aminoalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylamino-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) haloalkyl, substituted or unsubstituted (C2-C6) alkenyl, substituted or unsubstituted (C2-C6) alkynyl, linking group attached to a second CSA, substituted or unsubstituted (C1-C18) aminoalkyloxy, substituted or unsubstituted (C1-C18) aminoalkyloxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) aminoalkylcarboxy (C1-C18) alkyl, substituted or unsubstituted (C1-C18) aminoalkylaminocarbonyl, substituted or unsubstituted (C1-C18) aminoalkylcarboxamido, substituted or unsubstituted di(C1-C18 alkyl) aminoalkyl, substituted or unsubstituted C-carboxy-(C1-C18) alkyl, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, substituted or unsubstituted (C1-C18) azidoalkyloxy, substituted or unsubstituted (C1-C18) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O, substituted or unsubstituted (C1-C18) guanidinoalkyloxy, substituted or unsubstituted (C1-C18) quaternary ammonium alkylcarboxy, and substituted or unsubstituted (C1-C18) guanidinoalkylcarboxy, where Q5 is a side chain of an amino acid and P.G. is an amino protecting group. 2. The method of claim 1, wherein R18 has the following structure: —R20—(C═O)—N—R21R22 wherein, R20 is a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted aryl; andR21 and R22 are independently selected from the group consisting of hydrogen, a substituted or unsubstituted C1-C24 alkyl, a substituted or unsubstituted C2-C24 alkenyl, a substituted or unsubstituted C2-C24 alkynyl, or a substituted or unsubstituted C6 or C10 aryl, 5 to 10 membered heteroaryl, 5 to 10 membered heterocyclyl, C7-13 aralkyl, (5 to 10 membered heteroaryl)-C1-C6 alkyl, C3-10 carbocyclyl, C4-10 (carbocyclyl)alkyl, (5 to 10 membered heterocyclyl)-C1-C6 alkyl, amido, and an amine protecting group, provided that at least one of R21 and R22 is not hydrogen. 3. The method of claim 1, wherein the tissue treatment composition is applied to an open wound for a period of time sufficient to cause closure of the wound. 4. The method of claim 1, wherein the tissue treatment composition is applied to a closed wound. 5. The method of claim 1, wherein the tissue treatment composition is applied to a tissue laceration or an incision site. 6. The method of claim 1, wherein the tissue treatment composition is applied to the tissue wound in at least four separate applications and/or over a period of at least 4 days. 7. The method of claim 1, wherein the tissue treatment composition is applied to the tissue wound by spraying. 8. The method of claim 1, wherein the CSA compound is administered from a pharmaceutically acceptable device selected from the group consisting of bandages, surgical dressings, gauzes, adhesive strips, surgical staples, clips, hemostats, intrauterine devices, sutures, trocars, catheters, tubes, and implants. 9. The method of claim 1, wherein the subject is a vertebrate. 10. The method of claim 1, wherein the subject is mammal. 11. The method of claim 10, wherein the subject is a non-human mammal. 12. The method of claim 10, wherein the subject is a human, horse, or dog. 13. The method of claim 10, wherein the subject is a newborn and the tissue wound is a navel of the newborn. 14. The method of any claim 1, wherein the tissue treatment composition is for veterinary use. 15. The method of claim 1, wherein the tissue wound is a burn. 16. The method of claim 1, wherein the tissue wound is not a burn. 17. The method of claim 1, wherein the tissue wound includes a chronic infection. 18. The method of claim 1, wherein the tissue treatment composition includes the CSA in a concentration in a range between 0.01-5% wt/wt. 19. The method of claim 1, wherein the tissue treatment composition includes the CSA in a concentration in a range between about 0.01-2.0% wt/wt. 20. The method of claim 1, wherein the plurality of cationic groups are each attached to the steroidal group through a hydrolysable ester linkage. 21. The method of claim 1, wherein the CSA compound has the Formula (Ia). 22. The method of claim 21, wherein at least R3, R7, and R12 of Formula Ia are independently an aminoalkyloxy or an aminoalkylcarboxy. 23. The method of claim 21, wherein R18 of Formula Ia is selected from the group consisting of alkylaminoalkyl, di(alkyl)aminoalkyl, alkoxycarbonylalkyl, alkylcarboxyalkyl, C-carboxyalkyl, and alkylcarbonyloxyalkyl. 24. The method of claim 21, wherein R18 has the following structure: —R20—(C═O)—N—R21R22 wherein, R20 is a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted aryl; andR21 and R22 are independently selected from the group consisting of hydrogen, a substituted or unsubstituted C1-C24 alkyl, a substituted or unsubstituted C2-C24 alkenyl, a substituted or unsubstituted C2-C24 alkynyl, or a substituted or unsubstituted C6 or C10 aryl, 5 to 10 membered heteroaryl, 5 to 10 membered heterocyclyl, C7-13 aralkyl, (5 to 10 membered heteroaryl)-C1-C6 alkyl, C3-10 carbocyclyl, C4-10 (carbocyclyl)alkyl, (5 to 10 membered heterocyclyl)-C1-C6 alkyl, amido, and an amine protecting group, provided that at least one of R21 and R22 is not hydrogen. 25. The method of claim 1, wherein the CSA compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of: pharmaceutically acceptable salts thereof. 26. The method of claim 1, wherein the CSA compound, or a pharmaceutically acceptable salt thereof, is: or a pharmaceutically acceptable salt thereof. 27. A method of increasing the rate of healing of a tissue wound, comprising: identifying a subject in need of accelerated healing of a tissue wound; andcontacting the tissue wound with an effective amount of a tissue treatment composition to increase the rate of healing thereof, the tissue treatment composition comprising a cationic steroidal anti-microbial (CSA) compound of Formula Ia or pharmaceutically acceptable salt thereof that promotes wound healing: wherein, R3, R7, and R12 are independently selected from the group consisting of independently selected from the group consisting of hydrogen, an unsubstituted (C1-C22) alkyl, unsubstituted (C1-C22) hydroxyalkyl, unsubstituted (C1-C22) alkyloxy-(C1-C22) alkyl, unsubstituted (C1-C22) alkylcarboxy-(C1-C22) alkyl, unsubstituted (C1-C22) alkylamino-(C1-C22)alkyl, unsubstituted (C1-C22) alkylamino-(C1-C22) alkylamino, unsubstituted (C1-C22) alkylamino-(C1-C22) alkylamino-(C1-C18) alkylamino, an unsubstituted (C1-C22) aminoalkyl, an unsubstituted arylamino-(C1-C27) alkyl, an unsubstituted (C1-C22) aminoalkyloxy, an unsubstituted (C1-C22) aminoalkyloxy-(C1-C22) alkyl, an unsubstituted (C1-C22) aminoalkylcarboxy, an unsubstituted (C1-C22) aminoalkyl-aminocarbonyl, an unsubstituted (C1-C22) aminoalkylcarboxamido, an unsubstituted di(C1-C22 alkyl)aminoalkyl, unsubstituted (C1-C22) guanidinoalkyloxy, unsubstituted (C1-C22) quaternary ammonium alkylcarboxy, and unsubstituted (C1-C22) guanidinoalkyl carboxy, provided that at least two of R3, R7, and R12 are not hydrogen; andR18 is selected from the group consisting of substituted or unsubstituted (C1-C18) alkyl carboxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) alkylamino-(C1-C18) alkyl, substituted or unsubstituted amido, substituted or unsubstituted (C1-C18) aminoalkyl, linking group attached to a second CSA, substituted or unsubstituted (C1-C18) aminoalkyloxy, substituted or unsubstituted (C1-C18) aminoalkyloxy-(C1-C18) alkyl, substituted or unsubstituted (C1-C18) aminoalkylcarboxy (C1-C18) alkyl, and substituted or unsubstituted is alkyl) aminoalkyl. 28. The method of claim 27, wherein Rig has the following structure: —R20—(C═O)—N—R21R22 wherein, R20 is omitted or a substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl; andR21 and R22 are independently selected from the group consisting of hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, or a substituted or unsubstituted aryl, provided that at least one of R21 and R22 is not hydrogen. 29. A method of increasing the rate of healing of a tissue wound, comprising: identifying a subject in need of accelerated healing of a tissue wound; andcontacting the tissue wound with an effective amount of a cationic steroidal anti-microbial (CSA) compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: pharmaceutically acceptable salts thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.